Form 4: Cogent Bio CMO Reports Future Equity Transactions

Cogent Biosciences' Chief Medical Officer, Jessica Sachs, filed a Form 4 detailing future equity transactions including RSU vesting, tax-related share disposition, and new stock option grants effective December 17, 2025.

Summary

• Jessica Sachs, Chief Medical Officer of Cogent Biosciences, Inc. (COGT), reported several equity transactions effective December 17, 2025.
• Acquired 50,000 shares of common stock through an award of Restricted Stock Units (RSUs) under the Issuer's 2018 Stock Option and Incentive Plan, with a vesting schedule of 1/4th annually over four years.
• Acquired 320,000 shares of common stock due to the vesting of a performance-based RSU award granted in February 2023 (2023 PSUs).
• Disposed of 154,716 shares of common stock at a price of $39.45 per share to cover required tax withholdings related to the vesting of the 2023 PSUs.
• Received a grant of 65,000 stock options (right to buy) with an exercise price of $39.45, vesting in equal monthly installments over a four-year period.
• Following these transactions, Jessica Sachs beneficially owns 216,580 shares of common stock (including unvested RSUs) and 65,000 stock options.

Sentiment

Score: 6

Explanation: The filing reports standard executive compensation events, including grants of restricted stock units and stock options, and the vesting of performance-based awards. While shares were disposed for tax purposes, this is a routine occurrence. The overall sentiment is neutral to slightly positive as it reflects ongoing executive compensation and retention.

Positives

• The Chief Medical Officer received a grant of 50,000 new Restricted Stock Units (RSUs), indicating continued long-term incentive and retention.
• The vesting of 320,000 performance-based RSUs demonstrates the achievement of previously set performance criteria.
• A new grant of 65,000 stock options provides additional long-term equity incentive for the executive.

Negatives

• 154,716 shares of common stock were disposed of to satisfy tax withholding obligations, which is a standard practice upon RSU vesting and not indicative of a negative outlook.

Future Outlook

The future outlook for the Chief Medical Officer's equity holdings includes the continued vesting of 50,000 RSUs over four years, with 1/4th vesting on each anniversary of the grant date, and the vesting of 65,000 stock options in equal monthly installments over a four-year period, both contingent on her continued service to the Issuer.

Industry Context

This Form 4 filing reports routine insider equity transactions for executive compensation, which is a standard practice across the biotechnology and pharmaceutical industries to align management incentives with shareholder interests. It does not provide broader industry trends or specific competitive insights.

Stakeholder Impact

• Aligns the interests of Chief Medical Officer Jessica Sachs with shareholders through equity ownership.
• Provides long-term incentive for executive retention and performance, potentially benefiting shareholders through sustained leadership.

Next Steps

• Continued vesting of 50,000 RSUs over four years, with 1/4th vesting annually, subject to continued service.
• Continued vesting of 65,000 stock options in equal monthly installments over four years, subject to continued service.

Key Dates

Keywords

Cogent Biosciences, COGT, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Chief Medical Officer, Executive Compensation